Physician profile
Peter K Kubitz
NPI 1750373718
$6,908.04
in general payments reported to CMS, 2019-2025
33 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,846 · 2020: $776 · 2021: $525 · 2022: $515 · 2023: $752 · 2024: $906 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,493.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $892.73 | 2019-2025 | Relistor |
| Nevro Corp. | $777.21 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $548.19 | 2019-2025 | Belbuca, Xtampza |
| Abbvie INC. | $530.39 | 2022-2025 | |
| Nalu Medical, INC. | $465.16 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic, INC. | $436.71 | 2022-2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $365.74 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $182.29 | 2022-2024 | Proclaim, Eterna |
| Stimwave Technologies Incorporated | $180.43 | 2019 | |
| Lundbeck LLC | $170.52 | 2025 | Vyepti |
| Saluda Medical Americas, INC. | $152.35 | 2024-2025 | Evoke |
| Teva Pharmaceuticals USA, INC. | $75.43 | 2020-2022 | |
| Mdd US Operations, LLC | $72.19 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $63.98 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $58.94 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.13 | 2022 | |
| Spr Therapeutics, INC | $37.22 | 2019 | |
| Biotronik Nro, INC. | $36.67 | 2024-2025 | Prospera |
| Vertos Medical, INC. | $35.71 | 2024 | Mild Device Kit |
| Fidia Pharma USA INC. | $33.01 | 2020-2021 | |
| Depuy Synthes Sales INC. | $32.00 | 2023-2024 | Monovisc, Orthovisc |
| West Therapeutics Development, LLC | $27.17 | 2019 | |
| Biodelivery Sciences International, INC. | $26.27 | 2020 | |
| Pfizer INC. | $25.86 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $22.99 | 2024 | Euflexxa |
| Vertex Pharmaceuticals Incorporated | $18.22 | 2025 | |
| Redhill Biopharma INC. | $16.86 | 2021 | |
| Zyla Life Sciences, INC. | $15.96 | 2020 | |
| Daiichi Sankyo INC. | $15.96 | 2019 | |
| Medtronic USA, INC. | $14.25 | 2019 | |
| Virtus Pharmaceuticals LLC | $14.21 | 2021 | |
| Lilly USA, LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kubitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.